Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics (RLAY), a clinical-stage precision medicine company, has announced its participation in two major investor conferences in March 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relay Therapeutics (RLAY), a clinical-stage precision medicine company, has announced its participation in two major investor conferences in March 2025. The company will be featured in fireside chat sessions at:
• TD Cowen's 45th Annual Health Care Conference on March 5, 2025, at 1:50 p.m. ET
• Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 11:00 a.m. ET
Both sessions will be accessible via live webcast through Relay Therapeutics' website in the News & Events section. Archived recordings will remain available for 30 days after each event. The company, known for combining computational and experimental technologies in drug discovery, makes these presentations available at https://ir.relaytx.com/news-events/events-presentations.
Details
News Market Reaction – RLAY
The recorded move for RLAY in the trading session of this news was -5.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats:
- TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 1:50 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 at 11:00 a.m. ET
The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.